WR's Momentum Trades Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : WR's Momentum Trades

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Wayne Rumball who wrote (7372)	6/19/2000 10:41:00 AM
From: Wayne Rumball	Read Replies (1) of 11130

HOUSTON, Jun 16, 2000 (BUSINESS WIRE) -- Pathobiotek Diagnostics Inc. (OTC BB: PBTK ; pathobiotek.com), a developer of products for the diagnosis and evaluation of treatment for multiple sclerosis (MS) and other immune disorders, announced the receipt of the "Certificate of Allowability" for the patent. The actual issuance of the patent is now a formality, which will occur within a few days after the paperwork is returned to the patent office. Our investigations have demonstrated that the Activating Virus (AV) is a novel virus found in humans with a variety of cancers and immunosuppressive diseases plus marmosets with wasting syndrome. Wasting syndrome in marmosets resembles AIDS in humans. AV is associated with cancerous cell lines and may be an cofactor in human tumors. Studies to further characterize the genetic composition of this virus are ongoing. The commercial value of this patent has enormous upside potential and could be of significant financial benefit to Pathobiotek. Additional information on Pathobiotek Diagnostics Inc. can be obtained at pathobiotek.com.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next